Aprea Therapeutics Inc (APRE) Stock Price, Quote & News

Company Profile

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers; and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid...

Industry: Biotechnology

Sector: Healthcare

Phone: (215) 948-4119

Website: aprea.com

Address:

3805 Old Easton Road, Doylestown, United States

IN0V8 Jun. 25 at 10:48 PM

$APRE https://www.globenewswire.com/news-release/2025/06/25/3105158/0/en/Aprea-Reports-Anti-Proliferative-Results-and-Promising-Early-Stage-Clinical-Data-for-Next-Generation-WEE1-Inhibitor-APR-1051-in-HPV-Head-and-Neck-Squamous-Cell-Carcinoma-HNSCC-in-C.html

0 · Reply

IN0V8 Jun. 25 at 4:33 PM

$APRE https://www.tradingview.com/news/reuters.com,2025:newsml_TUA42LKT3:0-aprea-reports-promising-early-data-for-wee1-inhibitor-in-hpv-hnscc-with-md-anderson/

0 · Reply

IN0V8 Jun. 25 at 3:25 PM

$APRE Bought @ $1.49

0 · Reply

frankyboyz Jun. 25 at 1:37 PM

4m floater $APRE cancer news in pm and didnt move yet... watching for a 2 break play with vol could have room to 3/4 Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center

0 · Reply

OpenOutcrier Jun. 25 at 1:03 PM

$APRE (+14.6% pre) Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) https://ooc.bz/l/68613

0 · Reply

TA_Kongen Jun. 25 at 1:02 PM

$APRE Initial clinical data limited to only one patient. Nice try lmfao.

0 · Reply

IN0V8 Jun. 23 at 2:20 PM

$APRE Bought at $1.52

0 · Reply

twighttrades1 Jun. 20 at 12:58 AM

$APRE - im fully alive here in this one- long in mid $2’s as ive been nibbling for 5 months- not a lot of stock out there- something will give

0 · Reply

Gbeezy Jun. 19 at 1:56 PM

$APRE let him cook

0 · Reply

sarastocktwits May. 29 at 4:15 PM

$APRE long time due..push it over 10$

0 · Reply

Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center

May 14, 2025, 8:00 AM EDT - 6 weeks ago

Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update

Mar 31, 2025, 8:30 AM EDT - 3 months ago

Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial

Mar 25, 2025, 8:30 AM EDT - 3 months ago

Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Mar 11, 2025, 8:30 AM EDT - 3 months ago

Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)

Feb 5, 2025, 8:00 AM EST - 5 months ago

Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics

Dec 11, 2024, 8:30 AM EST - 7 months ago

Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward

Oct 23, 2024, 8:30 AM EDT - 8 months ago

Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

Oct 14, 2024, 8:30 AM EDT - 9 months ago

Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit

Oct 10, 2024, 8:30 AM EDT - 9 months ago

Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

Oct 9, 2024, 8:30 AM EDT - 9 months ago

Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development

Sep 9, 2024, 5:15 PM EDT - 10 months ago

UPDATE - Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference

Sep 9, 2024, 4:05 PM EDT - 10 months ago

Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference

Aug 12, 2024, 8:30 AM EDT - 11 months ago

Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Jun 21, 2024, 8:00 AM EDT - 1 year ago

Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024

Jun 17, 2024, 8:30 AM EDT - 1 year ago

Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051

May 28, 2024, 8:45 AM EDT - 1 year ago

Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial

May 14, 2024, 8:30 AM EDT - 1 year ago

Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update

May 13, 2024, 4:01 PM EDT - 1 year ago

Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference

May 2, 2024, 9:15 AM EDT - 1 year ago

Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D.

Apr 10, 2024, 12:00 PM EDT - 1 year ago

Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024

Mar 26, 2024, 7:45 AM EDT - 1 year ago

Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Mar 14, 2024, 7:48 AM EDT - 1 year ago

Karolinska Development's portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 million

Mar 11, 2024, 8:30 AM EDT - 1 year ago

Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million

Mar 11, 2024, 8:29 AM EDT - 1 year ago

Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers

Mar 5, 2024, 4:45 PM EST - 1 year ago

Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024

Feb 6, 2024, 8:01 AM EST - 1 year ago

Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor

Jan 30, 2024, 8:00 AM EST - 1 year ago

Aprea Therapeutics to Present at DDR Inhibitors Summit 2024

Jan 4, 2024, 4:05 PM EST - 1 year ago

Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024

Nov 9, 2023, 4:05 PM EST - 1 year ago

Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update

Oct 16, 2023, 8:30 AM EDT - 1 year ago

Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio

Sep 19, 2023, 8:00 AM EDT - 1 year ago

Aprea Therapeutics Announces Two Posters at the Upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 11, 2023, 8:00 AM EDT - 1 year ago

Aprea Announces Preclinical Data Supporting Highly Differentiated WEE1 Inhibitor, ATRN-1051, Relative To Other WEE1 Inhibitors

Sep 6, 2023, 4:05 PM EDT - 1 year ago

Aprea Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 24, 2023, 7:30 AM EDT - 2 years ago

Aprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as Chairman

Aug 10, 2023, 7:30 AM EDT - 2 years ago

Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations

Jun 14, 2023, 8:00 AM EDT - 2 years ago

Aprea Therapeutics to Present at Maxim Virtual Healthcare Conference

May 30, 2023, 8:30 AM EDT - 2 years ago

Aprea Therapeutics to Present at BIO International Convention

May 15, 2023, 4:05 PM EDT - 2 years ago

Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations

May 8, 2023, 8:00 AM EDT - 2 years ago

Aprea Therapeutics Appoints Gabriela Gruia, M.D. to Board of Directors

Mar 30, 2023, 4:05 PM EDT - 2 years ago

Aprea Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Update on Business Operations

Mar 16, 2023, 8:00 AM EDT - 2 years ago

Aprea Therapeutics Announces Presentation of Preclinical Data on Pipeline Programs at the AACR 2023 Annual Meeting

Mar 1, 2023, 4:05 PM EST - 2 years ago

Aprea Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Feb 27, 2023, 4:05 PM EST - 2 years ago

Aprea Therapeutics Announces Closing of $5.5 Million Underwritten Public Offering of Common Stock

Feb 22, 2023, 8:41 PM EST - 2 years ago

Aprea Therapeutics Announces Pricing of $5.5 Million Underwritten Public Offering of Common Stock

Feb 13, 2023, 7:00 AM EST - 2 years ago

Aprea Therapeutics Announces One-for-Twenty Reverse Stock Split

Jan 30, 2023, 8:00 AM EST - 2 years ago

Aprea Therapeutics Appoints John Hamill as Chief Financial Officer

Jan 19, 2023, 8:00 AM EST - 2 years ago

Aprea Therapeutics to Participate in 6th Annual DNA Damage and Response (DDR) Inhibitors Summit

Jan 12, 2023, 5:39 AM EST - 2 years ago

Karolinska Development's portfolio company Aprea Therapeutics doses the first patient in a clinical phase 1/2a study of ATRN-119

Nov 9, 2022, 4:15 PM EST - 2 years ago

Aprea Therapeutics Reports Third Quarter 2022 Financial Results and Provides Update on Business Operations

IN0V8 Jun. 25 at 10:48 PM

0 · Reply

IN0V8 Jun. 25 at 4:33 PM

$APRE https://www.tradingview.com/news/reuters.com,2025:newsml_TUA42LKT3:0-aprea-reports-promising-early-data-for-wee1-inhibitor-in-hpv-hnscc-with-md-anderson/

0 · Reply

IN0V8 Jun. 25 at 3:25 PM

$APRE Bought @ $1.49

0 · Reply

frankyboyz Jun. 25 at 1:37 PM

0 · Reply

OpenOutcrier Jun. 25 at 1:03 PM

0 · Reply

TA_Kongen Jun. 25 at 1:02 PM

$APRE Initial clinical data limited to only one patient. Nice try lmfao.

0 · Reply

IN0V8 Jun. 23 at 2:20 PM